{
    "organizations": [],
    "uuid": "3f75dea761a41837d9296e970169301c9bcd75c7",
    "author": "Reuters Editorial",
    "url": "https://www.reuters.com/article/brief-alnylam-pharmaceuticals-q4-non-gaa/brief-alnylam-pharmaceuticals-q4-non-gaap-loss-per-share-1-20-idUSASB0C4S0",
    "ord_in_thread": 0,
    "title": "BRIEF-Alnylam Pharmaceuticals Q4 Non-Gaap Loss Per Share $1.20",
    "locations": [],
    "highlightText": "",
    "language": "english",
    "persons": [],
    "text": "Feb 8 (Reuters) - Alnylam Pharmaceuticals Inc:\n* ALNYLAM PHARMACEUTICALS REPORTS FOURTH QUARTER AND FULL YEAR 2017 FINANCIAL RESULTS AND HIGHLIGHTS RECENT PERIOD ACTIVITY\n* Q4 NON-GAAP LOSS PER SHARE $1.20 * EXPECTS TO END 2018 WITH APPROXIMATELY $1.0 BILLION IN CASH\n* REAFFIRMED GUIDANCE TO INITIATE A COMPREHENSIVE PHASE 3 PROGRAM FOR ALN-TTRSC02 IN LATE 2018\n* QTRLY LOSS PER SHARE $1.48 * REVENUES WERE $37.9 MILLION IN Q4 OF 2017, AS COMPARED TO $17.5 MILLION IN Q4 OF 2016\n* Q4 EARNINGS PER SHARE VIEW $-1.39 -- THOMSON REUTERS I/B/E/S\n* EXPECTS 2018 ANNUAL NON-GAAP RESEARCH AND DEVELOPMENT EXPENSES TO BE IN RANGE OF $400 MILLION TO $440 MILLION\n* Q4 REVENUE VIEW $21.8 MILLION -- THOMSON REUTERS I/B/E/S Source text for Eikon: Further company coverage:\n ",
    "published": "2018-02-08T21:07:00.000+02:00",
    "crawled": "2018-02-09T16:51:41.001+02:00",
    "highlightTitle": "",
    "preprocessed_text": [
        "feb",
        "reuters",
        "alnylam",
        "pharmaceutical",
        "inc",
        "alnylam",
        "pharmaceutical",
        "report",
        "fourth",
        "quarter",
        "full",
        "year",
        "financial",
        "result",
        "highlight",
        "recent",
        "period",
        "activity",
        "q4",
        "loss",
        "per",
        "share",
        "expects",
        "end",
        "approximately",
        "billion",
        "cash",
        "reaffirmed",
        "guidance",
        "initiate",
        "comprehensive",
        "phase",
        "program",
        "late",
        "qtrly",
        "loss",
        "per",
        "share",
        "revenue",
        "million",
        "q4",
        "compared",
        "million",
        "q4",
        "q4",
        "earnings",
        "per",
        "share",
        "view",
        "thomson",
        "reuters",
        "expects",
        "annual",
        "research",
        "development",
        "expense",
        "range",
        "million",
        "million",
        "q4",
        "revenue",
        "view",
        "million",
        "thomson",
        "reuters",
        "source",
        "text",
        "eikon",
        "company",
        "coverage"
    ]
}